Thomas VanCott joins Excellos as new CEO

Thomas VanCott, CEO

Excellos Announces Acceleration of Commercialization, New CEO, Thomas VanCott New investment funds expansion of commercial team SAN DIEGO. CA, May 7, 2024, – Excellos Inc., a cell therapy contract and development manufacturing organization (CDMO), today announced it had taken additional investment to accelerate commercialization efforts. As part of the change new CEO Thomas VanCott, Ph.D., […]

Allogeneic Cell Therapy Advances at AACR 2024

allogeneic cell therapy advances on display at AACR 2024

American Association for Cancer Research (AACR) held their 2024 annual meeting in San Diego CA. This conference served as a platform for groundbreaking advancements in allogeneic cell therapy highlighted across a range of diseases.   Safeguarding allogeneic cell therapy products Among the noteworthy developments were discoveries from Century Therapeutics whose presentation of preclinical data revealed […]

3 Key Bottlenecks in Cell Therapy Supply Chains

cell therapy supply chain

Cell Therapy Supply Chain With 1920 ongoing clinical trials as of Q4 2023, the pipeline for new therapies is rich in diversity of diseases under investigation and is continuing to grow. A major follow-on question is whether the gene and cell therapy supply chain is ready to handle what may be a tidal wave of […]

Autoimmune Therapy Excitement Builds at Advanced Therapies Week 2024

Excellos at Advanced Therapies Week 2024

Robust pipeline demonstrated at Advanced Therapies Week 2024 As we reflect on the monumental strides made in 2023 within the field of cell and gene therapy, Advanced Therapies Week 2024 served as an inspiring launchpad for the year ahead. Groundbreaking approvals like gene therapies for sickle cell disease brought hope for rare illnesses, while advances […]

Excellos Announces Strategic Partnership and Investment from Vitalant

Excellos and Vitalant strategic partnership

Strategic Partnership With Vitalant to Bring Better Therapies to Patients Partnership to deliver enhanced donor profiles for higher potency cell therapeutics SAN DIEGO. CA, January 17, 2024, – Excellos Inc., a cell therapy contract and development manufacturing organization (CDMO), today announced a new partnership with Vitalant, one of the nation’s largest nonprofit blood and biotherapies […]

Excellos is excited to partner with TC BioPharm to enable novel cell therapies

TC BioPharm selects Excellos as CDMO for T cell therapies

TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements EDINBURGH, Scotland, Oct. 25, 2023 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced it has selected Excellos, a San Diego based […]

Excellos Opens Cutting-Edge Cell Therapy GMP Manufacturing Facility in Downtown San Diego

cell therapy GMP manufacturing

June 27, 2023; San Diego, California – Excellos Opens Cutting-Edge Cell Therapy GMP Manufacturing Facility in Downtown San Diego. Cell Therapy GMP Manufacturing Facility Excellos, a full-service contract development and manufacturing organization (CDMO) for cell therapy, proudly announces the opening of their cell therapy GMP manufacturing facility in the heart of downtown San Diego. The facility […]

Excellos Launches ‘Excellos 360’ Alongside RUO and GMP Product Portfolio to Reduce Clinical Response Variability

Excellos 360

The central aims of Excellos 360 are to reduce clinical response variability and possibly improve outcomes, lower safety liability by allowing effectiveness in lower dosages and reducing the cost of goods associated with advanced therapies. January 17, 2023; San Diego, California – Excellos, the California-based, full-service CDMO, has today announced the launch of ‘Excellos 360’, […]

Single-Cell Analysis of T Cells – Improved Prediction of Disease Risk

Single-Cell analysis T-Cells Excellos Blog

The La Jolla researchers are studying how small changes in gene expression can influence the function of immune cells during infection. Single-cell analysis was performed on activated CD4+ T cells from 89 healthy donors. It turns out that the old adage of “one gene, one protein” is not precisely true. In reality, as research on […]

Stem Cell Transduction Efficiency – Managing Donor Variance

Managing Donor Variance in Stem Cell Transduction Efficiency

Gene therapy, and in particular, therapy involving genetically modified stem cells, is one of the most promising methods for treating genetic disease and defects, and has therefore become a popular focus of research and development. In recent years, using adenoviral vectors to deliver modified genes has become standard practice. Adeno-associated viruses (AVVs) are easy to […]